Dose Volume Histogram Dvh Evaluator
Diversilabs
FDA Clearance Information
The dose volume histogram DVH evaluator was cleared by the FDA via the 510(k) pathway on December 16, 2009. Manufactured by Diversilabs, it is classified as a Class 2 device under product code MUJ.
What It Is
FDA-Cleared Indications
- For evaluation of dose-volume relationships in radiation therapy treatment plans.
- For clinical analysis of radiation dose distributions.
Clinical Applications
- Reviewing radiation dose distributions during treatment planning.
- Assessing the dose delivered to target treatment volumes.
- Evaluating dose exposure to surrounding organs and healthy tissues.
- Supporting patient-specific radiation therapy plan review and quality assurance.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- This is a software-based evaluation device rather than an implanted or physically inserted device.
- Compatibility depends on the radiation treatment-planning system, imaging data formats, and dose-reporting workflows used by the clinic.
- A DVH summarizes dose by volume and should be interpreted with the full treatment plan, dose distribution, target contours, and organ-at-risk contours.
- The device does not independently deliver radiation or replace clinical review by a qualified radiation oncology team.
- MRI safety considerations generally apply to the imaging system and associated hardware, not to the DVH evaluation software itself.
Frequently Asked Questions
What are the clinical indications for dose volume histogram dvh evaluator?
The device is indicated for use in evaluating radiation dose distributions in treatment planning, particularly in radiation oncology for cancers such as head and neck and cervix.
What outcomes have been reported in clinical studies?
Clinical studies have reported improved precision in dose-volume histogram calculations and enhanced treatment planning consistency.
What complications have been reported?
Safety data indicate potential calculation discrepancies due to system-specific variations, but no significant adverse events have been reported.